2. Academic Validation
  3. Antagonistic nanobodies implicate mechanism of GSDMD pore formation and potential therapeutic application

Antagonistic nanobodies implicate mechanism of GSDMD pore formation and potential therapeutic application

  • Nat Commun. 2024 Sep 26;15(1):8266. doi: 10.1038/s41467-024-52110-1.
Lisa D J Schiffelers 1,  Yonas M Tesfamariam 1,  Lea-Marie Jenster 1,  Stefan Diehl 1,  Sophie C Binder 1,  Sabine Normann 1,  Jonathan Mayr 1,  Steffen Pritzl 1,  Elena Hagelauer 1,  Anja Kopp 2 3,  Assaf Alon 4,  Matthias Geyer 2,  Hidde L Ploegh 4,  Florian I Schmidt 5 6 7
Affiliations

Affiliations

  • 1 Institute of Innate Immunity, Medical Faculty, University of Bonn, Bonn, Germany.
  • 2 Institute of Structural Biology, Medical Faculty, University of Bonn, Bonn, Germany.
  • 3 Inflammation Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, Australia.
  • 4 Whitehead Institute for Biomedical Research, Cambridge, MA, USA.
  • 5 Institute of Innate Immunity, Medical Faculty, University of Bonn, Bonn, Germany. fschmidt@uni-bonn.de.
  • 6 Whitehead Institute for Biomedical Research, Cambridge, MA, USA. fschmidt@uni-bonn.de.
  • 7 Core Facility Nanobodies, Medical Faculty, University of Bonn, Bonn, Germany. fschmidt@uni-bonn.de.
PMID: 39327452 DOI: 10.1038/s41467-024-52110-1
Abstract

Inflammasome activation results in the cleavage of gasdermin D (GSDMD) by pro-inflammatory caspases. The N-terminal domains (GSDMDNT) oligomerize and assemble pores penetrating the target membrane. As methods to study pore formation in living cells are insufficient, the order of conformational changes, oligomerization, and membrane insertion remained unclear. We have raised nanobodies (VHHs) against human GSDMD and find that cytosolic expression of VHHGSDMD-1 and VHHGSDMD-2 prevents oligomerization of GSDMDNT and Pyroptosis. The nanobody-stabilized GSDMDNT monomers partition into the plasma membrane, suggesting that membrane insertion precedes oligomerization. Inhibition of GSDMD pore formation switches cell death from Pyroptosis to Apoptosis, likely driven by the enhanced Caspase-1 activity required to activate Caspase-3. Recombinant antagonistic nanobodies added to the extracellular space prevent Pyroptosis and exhibit unexpected therapeutic potential. They may thus be suitable to treat the ever-growing list of diseases caused by activation of (non-) canonical inflammasomes.

Figures
Products
我们的 Cookie 政策

我们使用 Cookies 和类似技术以提高网站的性能和提升您的浏览体验，部分功能也使用 Cookies 帮助我们更好地理解您的需求，为您提供相关的服务。 如果您有任何关于我们如何处理您个人信息的疑问，请阅读我们的《隐私声明》。

嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z